Neuromodulación farmacológica en la enfermedad cerebrovascular

Revista Cubana de Medicina

Volumn 41, Issue 2, 2002, Pages 104-110

  Rodríguez Mutuberría, Liván ^a   Galvizu Sánchez, Reynaldo ^a   Álvarez González, Eduardo ^a  

^a CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 52649181125     PISSN: 00347523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Nitta A, Hayashi K, Hasegawa T, Nabeshima T. Development of plasticity of brain function with repeated trainings and passage of time after basal forebrain lesions in rats. J Neural Transm Gen Seet 1993;93:46.
2. Bonita R. Epidemiology of stroke. Lancet 1992;339:342-4.
3. Von Steinbuchel N, Poppel E. Domains of rehabilitation: a theorical perspective. Behav Brain Res 1993;56:1-10.
4. Pulsinelle WA. Pathophysiology of acute ischemic stroke. Lancet 1992;339:533-6.
5. Allain H, Decombe R, Saiag B, Bentué-Ferrer D, Guez D. Mechanis-tic basis for the development of anti-ischemic drugs. Cerebrovasc Dis 1991;(Suppl 1):83-92.
6. Dávalos A, Castillo J, Martínez-Vila E. Delay in neurological attention and stroke outcome. Stroke 1995;26:2233-7.
7. Pulsinelli WA. The therapeutic window in ischemic brain injury. Curr Opin Neurol 1995;8:3-5.
8. Baron JC, von Kumar R, del Zoppo GJ. Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window. Stroke 1995;26:2219-21.
9. Martínez-Vila E. Terapéutica de la isquemia cerebral focal. En Matías-Guiu J, Martínez-Vila E, Martí-Vilalta JL, eds. Isquemia cerebral. Barcelona: MCR; 1990. p. 231-3.
10. Raichle ME. The pathophysiology of brain ischemia. Ann Neurol 1983;13:2-10.
11. Hass WK. The cerebral ischemic cascade. Neurol Clin 1983;1:345-53.
12. Onal MZ, Fisher M. Acute ischemic stroke therapy. A clinical overview. Eur Neurol 1997;38:141-54.
13. Gelmers HJ, Gorter K, de Weerdt CJ, Wiezer HJ. A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med 1988;318:203-7.
14. Norris JW, LeBrun LH, Anderson BA (the Canwin Study Group). Intravenous nimodipine in acute ischemic stroke. Cerebrovasc Dis 1994;4:194-6.
15. Wahlgren NG, MacMahon DG, de Keyser J, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994;4:204-10.
16. Bridgers S, Koch G, Munera C, Karwon M, Kurtz N. Intravenous nimodipine in acute stroke: interim analysis of randomized trial. Stroke 1991;22:29.
17. Teal P on behjalf of the BRAIN Study Group. BRAINS, a phase II study of the neuroprotectant BAY 3102 in patients with ischemic stroke. Cerebrovasc Dis 1998;8:(Suppl 4):S20.
18. Muir KW, Lees KR. A randomized, double-blind, placebo controlled pilot trial of intravenous magnesium sulphate in acute stroke. Stroke 1995; 26:1183-8.
19. _. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503-13.
20. García JH. The evolution of brain infarcts. A review. J Neuropathol Exp Neurol 1992;51:387-93.
21. Astrup J, Siesjo BK, Symon L. Threshold in cerebral ischemia. The ischemic penumbra. Stroke 1981;12:723-7.
22. Matías-Guiu J, Martínez-Vila E. Isquemia cerebral y neuroprotección. Barcelona: Sintex Latino; 1988.
23. Ginsberg MD. Neuroprotection in brain ischemia: an update (part 1). The Neuroscientist 1995;1:95-103.
24. _. Neuroprotection in brain ischemia: an update (part II). The Neuroscientist 1995;1:164-75.
25. Devuyst G, Gogousslavsky J. Clinical trial update: neuroprotection against acute ischemic stroke. Curr Opin Neurol 1999;12:73-9.
26. Diener HC, Hacke W Hennerici M, Radberg J, Hantson L, de Keyser J. Lubeluzole in acute ischemic stroke: a double-blind, placebo-controlled phase II trial. Stroke 1996;27:76-81.
27. Grotta J, for the US and Canadian Lubeluzole Ischemic Stroke Study Group. Lubeluzole treatment of acute ischemic stroke. Stroke 1997;28:2338-46.
28. Siesjo BK, Agarddh CD, Bengtsson F. Free radicals and brain damage. Cerebrovasc Brain Metab Rev 1989;1:165-211.
29. Schmidley JW. Free radicals in central nervous system ischemia. Stroke 1990;21:1086-90.
30. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, et al for the Ebselen Study Group. Ebselen in acute ischemic stroke. A placebo-controlled, double-blind clinical trial. Stroke 1998;29:12-7.
31. Haley EC, for the STIPS investigators: safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). STROKE 1994;25:418-23.
32. The RANTTAS investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 1996;27:1453-7.
33. Haley EC on behalf of the RANTTAS II investigators. High dose tirilazad for acute stroke (RANTTAS II). Stroke 1998;29:1256-7.
34. Muller WE, Koch S, Scheuer K, Rostock A, Bartsch R. Effects of piracetamon membrane fluidity in the aged mouse, rat and human brain. Biochem Pharmacol 1997;53:135-40.
35. De Deyn PP, de Reuck, Debert W et al. Treatment of acute ischemic stroke with piracetam. Stroke 1997;28:2347-52.
36. Pam Enderby. The efficacy and safety of piracetam in the rehabilitation of stroke patients. Int Acad Biomed Drug Res. Basel, Karger 1994;7:249-55.
37. D'.Orlando JK, Sandadge BW Citicoline (CDP-Choline): mechanisms of action and effects ischemic brain injury. Neurol Res 1995;17:281-4.
38. Corso EA, Arena M, Ventimiglia A, et al. CDP-Choline for cerebrovascular disorders. Clinical evaluation and evaluation of electrophysiological symptomatology. Clin Ter 1982;102:379-86.
39. Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA, for the Citicoline Stroke Study Group. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology 1997;49:671-8.
40. Bruhwyler J, van Dorpe J, Geczy J. Multicentric open-label study of the efficacy and tolerability of citicoline in the treatment of acute cerebral infarction. Curr Ther Res 1997;58:309-16.
41. Tazaki Y, Sakai F, Otomo E, Kutsuzawa T, Kameyama M, Omae T, et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 1988;19:211-6.
42. Hazama T, Hasegawa T, Ueda S, Sakuma A. Evaluation of the effect of CDP-choline on poststroke hemiplegia employing a double-blind controlled trial: assesed by a new rating scale for recovery in hemiplegia. Int J Neurosci 1980;11:211-25.
43. Rossi M, Zanardi M. Studio in aperto sull' efficacia clinica della citicolina in pazienti affetti da cerebrovasculopatia cronica. Clin Ter 1993;142:141-4.
44. Ay H, Ay Y, Koroshetz WJ, Finklestein SP Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc Dis 1999;9:131-5.
45. Fiblast Safety Study Group. Clinical safety trial of intravenous basic fibroblast growth factor (bFGF, fiblast) in acute stroke. Stroke 1998;29:287.
46. Beck T, Lindholm D, Castre E, Wree A. Brain derived neurotrophic factor protects against ischemic cell damage in rat hippocampus. J Cereb Blood Flow Metab 1994;14:689-92.